In syngeneic sarcoma models, M002 did not produce any survival benefit compared to its parental virus R3659 (no IL-12 expression) [96], despite M002 inducing a significant anti-tumor immune effect over R3659 treatment, such as an increased percentage of intra-tumoral CD8+ T cells and activated monocytes, a decreased percentage of myeloid-derived suppressor cells (MDSCs), and increased CD8:MDSC and CD8:T regulatory cell ratios [96]. This evidence concerns the gene CD8A and neoplasm.